ThromBio’s Post

Agreed! The article by Sean Silcoff showcases how overcoming challenges such as real estate shortages and the need for a more supportive #investment climate can pave the way for monumental achievements in #biotechnology. A must-read for anyone keen on understanding the dynamics of creating a thriving #biotech #ecosystem in #Canada.

Transforming the Future of Biotechnology requires extraordinary resources, and as such calls for the expansion of the OcyonBio campus. As we pursue innovation and excellence, the construction of state-of-the-art facilities will help enable groundbreaking research and manufacturing methods to allow us and our cleints to transform the future of medicine. #OcyonBio #MakingMedicinesAffordable #AffordableMedicines #Future #CampusExpansion #BiotechExcellence #InnovationLeadership #FutureOfMedicine

Two Scientists, Two Paths: The Game-Changing Role of Patents in Biotech In the world of biotechnology, the difference between groundbreaking success and missed opportunities often comes down to one critical factor: patenting. Here's a tale of two scientists—one who leveraged patents to transform her career and another who overlooked their importance, highlighting why protecting innovation matters. Dr. Aditi Sharma: Turning Innovation into Impact Dr. Aditi Sharma, a leading researcher at an Indian University, is a shining example of leveraging patents strategically. Recognizing the value of intellectual property, she conducted detailed prior art searches to confirm her innovative drug delivery system's uniqueness. By identifying a gap in the market—more efficient drug delivery mechanisms—she designed a solution that not only met this need but also attracted interest from investors and pharmaceutical companies. She filed national and PCT patent applications, securing her invention globally. After patenting, Dr. Aditi published her research, enhancing her credibility in the scientific community. Her story is a testament to how patenting can pave the way for licensing opportunities and collaborations, turning ideas into impactful solutions. Dr. Ravi Kumar: A Cautionary Tale In contrast, Dr. Ravi Kumar’s groundbreaking gene therapy research remained unprotected. Without filing patents or conducting prior art searches, his work was left vulnerable to competitors, leading to missed funding and collaboration opportunities. What Can We Learn? Dr. Aditi’s journey shows how patenting can be a catalyst for success, while Dr. Ravi’s experience underscores the risks of neglecting intellectual property. For scientists, understanding the power of patents is key to transforming research into real-world impact. Secure your innovations. Embrace patents. Create a legacy. #innovation #patent #patentability #research

I am pleased to share my recent opinion piece in The Parliament, where I highlight the critical need for a stable and predictable regulatory framework to enhance the EU biotechnology sector’s competitiveness. Such a framework is essential for fostering innovation that leads to scientific breakthroughs, ultimately advancing societal health and benefiting patients and health systems. The upcoming Biotech Act presents a promising opportunity to achieve these goals. Let us work together to unlock the full potential of biotechnology. #MyCompany #Biotech #Innovation #EU

The Hidden Costs of Not Patenting: Dr. Ravi Kumar's Missed Opportunities Groundbreaking research can change the world—but only if the right strategic decisions are made. Dr. Ravi Kumar’s failure to secure patents for his gene therapy research is a powerful reminder of the risks innovators face without intellectual property protection. Here’s a look at the key hurdles that held back his transformative work. 🔒 Vulnerability to Competition Without patents, Dr. Kumar's research was unprotected, allowing competitors to replicate his ideas without facing legal consequences. This lack of intellectual property protection diminished his competitive advantage in a fast-moving industry. 💸 Missed Funding Opportunities Funding bodies are less likely to back unprotected research. Dr. Kumar’s unpatented work likely led to missed investment opportunities, as investors seek lower-risk, protected innovations. 🤝 Limited Collaboration Prospects Collaborations with pharmaceutical companies or research institutions are often contingent on patent ownership. Without patents, Dr. Kumar struggled to secure the partnerships that could have advanced his research. 🚫 Challenges in Commercialization The commercialization of scientific breakthroughs hinges on intellectual property rights. Without patents, Dr. Kumar lacked the leverage needed to attract interest from companies looking to license or develop his innovations. 📉 Reputational Impact In the scientific community, patents are seen as a mark of credibility. Dr. Kumar’s failure to patent his work likely impacted his standing among peers and hindered future collaborations. In summary, Dr. Ravi Kumar lost out on chances and the wider impact of his groundbreaking study because he neglected to get patents. This is a potent reminder to all researchers of how crucial intellectual property is to making sure that inventions become practical solutions. #Biotech #Innovation #PatentsMatter #GeneTherapy #Research #IntellectualProperty #ScientificImpact

Maryland ranks #3 for Biotech hub in USA. Exciting developments are in the BioHealth Capital Region through significant investments and expansions. 🔬 QIAGEN and Frederick County have completed a 40,000 sq. ft. expansion, focusing on next-gen sequencing and genomics. AstraZeneca plans a $300 million investment in a new Rockville, MD manufacturing site, creating 150 jobs by 2026. The University of Virginia is constructing a $300 million biotechnology institute in Charlottesville. 📉 Despite setbacks like Emergent BioSolutions announcing 300 job cuts and site closures, there are positive notes like selling a site to Bora Pharmaceuticals for $30 million. 💡 The BioHealth Capital Region excels in patents with 73,315 families and ranks third in NIH funding, securing $4.342 billion across 5,558 awards. Boasting 136,164 jobs and 35.9 million sq. ft. of lab space, the region is also advancing in venture capital, claiming fifth place with $1.92 billion in 2023 and $1.01 billion in early 2024. #BioHealth #Investments #Expansion #Biotechnology #Innovation

🧬 Archon Biosciences Emerges with $20M Seed Funding to Transform Biologic Drug Development TL;DR: • Startup launches with groundbreaking "antibody cage" technology • Founded by UW Institute for Protein Design alumni • Backed by Nobel laureate David Baker • 17-person team funded through 2026 Exciting developments in the protein design space! Archon Biosciences has emerged from stealth mode, introducing a revolutionary approach to enhancing biologic drugs through computational protein design. Led by CEO James Lazarovits, Archon's innovative "antibody cage" technology allows precise modification of antibody properties without altering their amino acid sequences - potentially streamlining drug development while maintaining therapeutic efficacy. The $20M seed round was led by Madrona Ventures, with Alexandria Venture Investments among key participants. The company joins an impressive lineup of ventures connected to David Baker's lab, including Sana Biotechnology and Lyell Immunopharma. What sets Archon apart? Their computational approach to molding antibodies into specific nanostructures could be a game-changer for drug distribution and binding properties. Looking ahead: The team is focused on identifying their lead program and pursuing additional funding for clinical trials. 💭 What are your thoughts on computational approaches to drug development? How do you see this technology impacting the future of biologics? #Biotech #DrugDevelopment #ProteinDesign #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

Top 5 Concerns Affecting the Life Sciences Industry: #3 (of 5)… “The BioSecure Act, under consideration in Congress, aims to restrict federal contracts with biotechnology firms… Linked to adversarial nations like China, Russia, Iran, and North Korea to secure the U.S. biotech supply chain and prevent espionage.” See the full article here: https://lnkd.in/dZHR6YPV

Day 3 at the Biotechnology Innovation Organization's annual conference! Yesterday our British Columbia Showcase put a spotlight on what makes our sector stand out and why we are making national news. Watch our sector snapshot video for some of the highlights. - We are home to Canada's largest life sciences companies STEMCELL Technologies StarFish Medical Xenon Pharmaceuticals Inc., to list a few. - Our sector has experienced double digit growth in recent years. - Biotech has attracted >US $13B in private investment over the past decade. - 20% of all Canadian spin-outs are from UBC. - The BC government invests heavily and identifies life sciences as a priority sector. - We are building infrastructure and developing talent to support our growth including in biomanufacturing and clinical trials. - Research innovation is a driving force with technologies developed and commercialized here. For example, we are home to lipid nanoparticle (LNP) technology that was a key constituent of early vaccines against COVID-19, and has multiple therapeutic applications. Thanks to support from Pacific Economic Development Canada | Développement économique Canada pour le Pacifique and the BC Provincial Government for helping us to profile BC at #BIO2024 and to biofilm MEDIA for the great work on this video. Wendy Hurlburt Ryan Butt

The #UniversityofDebrecen has partnered with #RichterGedeonPLC to enhance its innovation ecosystem, providing significant opportunities for its drug discovery experts. #research